patent.fyi
Applications  /  US 2026/0355163
United States Patent Application Publication

US 2026/0355163 A1

Published
Nov 12, 2026
Filed
Sep 1, 2023
Earliest date on the face
Sep 2, 2022
Classification
A61K 31/422
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Endoscopic bile duct clearance

What ifWhat if a clinician physically removed adult flukes from the common bile duct?
Claim language“administering to a mammal”

A side-viewing endoscope provides access to the bile duct through its opening in the duodenum. A retrieval balloon or basket sweeps adult flukes out of an obstructed duct and restores bile drainage.

1.1Sulfur heterocycle for adult flukes

What ifWhat if a sulfur-containing benzothiazole ring supplied the heterocyclic core of the active compound?
Claim language“X is O”

A veterinary suspension delivers a chlorinated benzothiazole with a methylsulfonyl substituent. The compound disrupts energy metabolism in susceptible adult liver flukes in the bile ducts.

1.1Salicylanilide amide scaffold

What ifWhat if an amide joined two aromatic rings in a halogenated salicylanilide?
Claim language“bond to the isoxazoline”

An ortho hydroxyl group on the benzoyl ring and electron-withdrawing substituents support proton transport across mitochondrial membranes. The salicylanilide dissipates the proton gradient and reduces ATP production in susceptible flukes.

1.1Iodinated nitrophenol scaffold

What ifWhat if a phenolic ring bearing directly bonded nitro, iodo, and nitrile groups supplied the active structure?
Claim language“denotes the bond to the carbonyl group”

The nitro and nitrile groups increase the acidity of the phenolic hydroxyl. The compound shuttles protons across the inner mitochondrial membrane and reduces ATP production in susceptible liver flukes.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Specific version of a part

Sulfur linked benzimidazole therapy

The mammal absorbs the benzimidazole and oxidizes its thioether group to a sulfoxide. The active metabolite disrupts tegument integrity and movement in susceptible immature and adult flukes.

Chloro and trifluoromethyl substitution

Chlorine occupies the R2 position, and a trifluoromethyl group occupies R4. Hydrogen occupies R1, R3, and R5, and oxygen occupies X.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,541,373 B2
Published
Jun 2, 2009
Filed
Mar 1, 2006
Class
A61K 31/426
Document BUS 2011/0301158 A1
Published
Dec 8, 2011
Filed
Aug 15, 2011
Class
A61K 31/5355
Claim 1
Document A
Document B
1.1administering to a mammal in need there of an effective amount of a compound of Formula (I) R1-R5 is H, F, Cl or CF3 X is O Y is selected from wherein denotes the bond to the isoxazoline denotes the bond to the carbonyl group Z is selected from wherein denotes the bond to the carbonyl group.
The present invention provides compounds as described below, pharmaceutical compositions comprising the compounds, their use for increasing the activity of glucokinase, their use in preparation of a medicament for treating said diseases and conditions and the use of compounds or pharmaceutical preparations of the present invention for treating said diseases and conditions as well as methods for treating said diseases and conditions, which methods comprise administering to a s
A · US 7,541,373 B2 · ¶ 23
The present invention provides a method of activating glucokinase, comprising the step of administering to a mammal in need thereof a pharmacologically effective amount of a compound according to the present invention.
B · US 2011/0301158 A1 · ¶ 1870

An empty cell means only that no passage was reproduced there.

Statements in these documents
This invention relates to compounds which are activators of glucokinase (GK), which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
A · US 7,541,373 B2 · ¶ 2
Since existing forms of therapy of diabetes does not lead to sufficient glycaemic control and therefore are unsatisfactory, there is a great demand for novel therapeutic approaches.
A · US 7,541,373 B2 · ¶ 7
This invention relates to compounds which are activators of glucokinase (GK), which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
B · US 2011/0301158 A1 · ¶ 2
Since existing forms of therapy of diabetes does not lead to sufficient glycaemic control and therefore are unsatisfactory, there is a great demand for novel therapeutic approaches.
B · US 2011/0301158 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355163 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355163/, SHA-256 c1eccdf177e1538094e0a21212551ee8583d5b61c914fe4d2207812f56471eec
First published
Permanent addresshttps://patent.fyi/US20260355163/
Content fingerprint (SHA-256)c1eccdf177e1538094e0a21212551ee8583d5b61c914fe4d2207812f56471eec
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi